PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.88%
Both companies show declining cash positions (-3.88% vs AGEN's -8.77%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-3.88%
Below half of AGEN's -8.43%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.86%
Other current assets growth 50-75% of AGEN's -20.01%. Bruce Berkowitz notes fewer expansions. Possibly simpler working capital.
-4.12%
Below half of AGEN's -12.98%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-3.46%
Below half AGEN's 9.20%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x AGEN's -0.03%. Michael Burry warns of potential hidden liabilities or intangible bloat.
-3.14%
Below half of AGEN's 6.19%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
0.5-0.75x AGEN's -5.95%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
36.45%
Less than half of AGEN's -3.15%. David Dodd sees a more disciplined AP approach or lower volume.
25.40%
Less than half of AGEN's -1.76%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-55.39%
≥ 1.5x AGEN's -10.10%. David Dodd sees stronger subscription/prepayment demand.
-25.40%
Less than half of AGEN's 27.47%. David Dodd sees fewer expansions in other current obligations.
32.92%
Above 1.5x AGEN's 8.36%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Less than half of AGEN's -5.31%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
4.45%
Less than half of AGEN's -0.38%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.53%
Similar yoy to AGEN's -3.42%. Walter Schloss sees parallel earnings retention vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.86%
Below half AGEN's -696.75%. Michael Burry sees potential underperformance in building shareholder capital.
-4.09%
0.5-0.75x AGEN's -5.95%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
-1.77%
1.25-1.5x AGEN's -1.26%. Martin Whitman is wary of bigger debt expansions vs. competitor.
3.93%
Less than half of AGEN's 12.83%. David Dodd sees better deleveraging or stronger cash buildup than competitor.